Synergistic Potential of Ecklonia cava and Oral Contraceptives inManaging Polycystic Ovary Syndrome: Clinical and BiochemicalEvaluation

ABSTRACTBackground: Polycystic Ovary Syndrome (PCOS) is a complex endocrine condition affecting women of reproductive age,influencing the endocrine, reproductive system, and metabolic processes.Objectives: To evaluate the anti-inflammatory and hormonal modulation effects of Ecklonia cava in PCOS patients.Methods: In this Randomized controlled study, 50 patients were diagnosed with polycystic ovary syndrome. Their agerange (18-40 years) was equally allocated into two groups. The Control group received Diane- 35 (2mg cyproteroneacetate/35 Mg ethinyl estradiol) once daily for 3 cycles, and the interventional group received a combination of Diane- 35plus 300 mg of Ecklonia cava once daily for 3 months. Parameters assessed before and after treatments course include:serum LH and FSH, oLH/FSH ratio, free testosterone, leptin HBA1c, IL-8, IL-10.Results: After 3 months, there was a significant reduction in the weight and waist circumference in the study group incomparison with the control group, with a p-value ≤0.05; significant improvement in LH, FSH, LH/FSH, Free testosteroneand leptin hormone, in addition significant reduction in IL-8, and increase IL-10 level.Conclusions: The addition of Eckonia cava to the Diane- 35 in the treatment of PCOS patients gives promising synergisticeffects in the regulation of clinical and biochemical parameters in PCOS. Patient